[HTML][HTML] The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy
DR Principe, PW Underwood, M Korc… - Frontiers in …, 2021 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
PP Adiseshaiah, RM Crist, SS Hook… - Nature reviews Clinical …, 2016 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related
deaths. PDAC remains one of the most difficult-to-treat cancers, owing to its unique …
deaths. PDAC remains one of the most difficult-to-treat cancers, owing to its unique …
Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
W Zhou, Y Zhou, X Chen, T Ning, H Chen, Q Guo… - Biomaterials, 2021 - Elsevier
Immunotherapy has gained increasing focus in treating pancreatic ductal adenocarcinoma
(PDAC), since conventional therapies like chemotherapy could not provide satisfactory …
(PDAC), since conventional therapies like chemotherapy could not provide satisfactory …
[HTML][HTML] Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer
S Mohammed, S Sukumaran, P Bajgain, N Watanabe… - Molecular therapy, 2017 - cell.com
The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …
[HTML][HTML] Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells
MFB Nielsen, MB Mortensen… - World journal of …, 2016 - ncbi.nlm.nih.gov
Pancreatic cancer (PC) is the most aggressive type of common cancers, and in 2014, nearly
40000 patients died from the disease in the United States. Pancreatic ductal …
40000 patients died from the disease in the United States. Pancreatic ductal …
Pancreatic cancer: Stroma and its current and emerging targeted therapies
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies
with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is …
with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is …
[HTML][HTML] Stroma-targeting therapy in pancreatic cancer: One coin with two sides?
B Jiang, L Zhou, J Lu, Y Wang, C Liu, L You… - Frontiers in …, 2020 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with one of the worst prognoses
worldwide and has an overall 5-year survival rate of only 9%. Although chemotherapy is the …
worldwide and has an overall 5-year survival rate of only 9%. Although chemotherapy is the …
Current progress in immunotherapy for pancreatic cancer
Pancreatic cancer remains one of the most lethal cancers with few treatment options.
Immune-based strategies to treat pancreatic cancer, such as immune checkpoint inhibitors …
Immune-based strategies to treat pancreatic cancer, such as immune checkpoint inhibitors …
Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer
W Zhou, X Chen, Y Zhou, S Shi, C Liang, X Yu, H Chen… - Biomaterials, 2022 - Elsevier
Despite tremendous progress achieved in immunotherapy, many critical challenges in
treating pancreatic ductal adenocarcinoma (PDAC) persist. Considering the poor …
treating pancreatic ductal adenocarcinoma (PDAC) persist. Considering the poor …
Axon guidance molecules promote perineural invasion and metastasis of orthotopic pancreatic tumors in mice
NR Jurcak, AA Rucki, S Muth, E Thompson, R Sharma… - Gastroenterology, 2019 - Elsevier
Background & Aims Little is known about mechanisms of perineural invasion (PNI) by
pancreatic ductal adenocarcinomas (PDAs) or other tumors. Annexin A2 (ANXA2) regulates …
pancreatic ductal adenocarcinomas (PDAs) or other tumors. Annexin A2 (ANXA2) regulates …